FDA has granted Diakonos Oncology Corporation’s investigational dendritic cell vaccine (DCV) Fast Track designation (FTD) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC).
Dr. Daniel D. Von Hoff, a renowned PDAC expert and Distinguished Professor at the Translational Genomics Research Institute (TGEN), has been appointed to the company’s Scientific Advisory Board. Dr. Von Hoff brings a wealth of experience in cancer research to the team.
Mike Wicks, CEO of Diakonos Oncology, acknowledged the FDA for the second FTD to the company’s DCV for PDAC.
He also welcomed Dr. Daniel D. Von Hoff to the Scientific Advisory Board. The first FTD was awarded to the vaccine for glioblastoma multiforme, which has shown significant improvements in 12-month survival rates.
Dr. Von Hoff focused on DCV for advanced PDAC and founded ILEX Oncology, which was acquired by Genzyme.
Diakonos’s unique DCV has shown encouraging results in treating glioblastoma, a terrible disease with few effective treatments.
Dr. Von Hoff stated that PDAC patients needed additional treatment options like DCV and expressed optimism about collaborating with Diakonos to develop effective treatments for PDAC using targeted technology.
Source: Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board
https://finance.yahoo.com/news/diakonos-oncology-receives-fda-fast-093000956.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cub25jb2xvZ3luZXdzY2VudHJhbC5jb20v&guce_referrer_sig
